Komori
Governance4512WAKAMOTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Corporate Governance Report 2025/06/25

The Company submitted a Corporate Governance Report dated 25 June 2025. The report presents the governance structure, including the Board of Directors, Audit and Supervisory Committee, and Nomination and Compensation Committee, as well as the skills of directors and executive officers, but does not specify changes from the previous report.

Worth reading
55In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Governance structure

Company with an Audit and Supervisory Committee
Number of directors9 directors (including 4 outside directors)
Committee4
指名報酬委員会サステナビリティ委員会リスク管理委員会コンプライアンス委員会
Governance structure
ItemDetails
Corporate Governance StructureCompany with an Audit and Supervisory Committee
Number of directors9 directors (including 4 outside directors)
Committee指名報酬委員会、サステナビリティ委員会、リスク管理委員会、コンプライアンス委員会(社外委員の割合はNot disclosed)
Items this document does not state (5)
Number of independent officersPolicy on cross-shareholdingsTakeover defensesControlling shareholderChanges this time

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The reason for any changes from the previous report is not provided.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Corporate Governance Report 2025/06/25 | WAKAMOTO PHARMACEUTICAL CO.,LTD. (4512) timely disclosure | Komori